Riley CH - Search Results

1

[Status and perspectives on chronic myeloproliferative neoplasm treatment].

Ocias LF, Holmström MO, Riley CH, Andersen CL, Rønnov-Jessen D, Starklint J, Frederiksen M, Steffensen MS, Bjerrum OW, Farmer S, Mourits-Andersen T, Hasselbalch HC, Larsen TS. Ocias LF, et al. Among authors: riley ch. Ugeskr Laeger. 2015 May 4;177(19):V12140652. Ugeskr Laeger. 2015. PMID: 25967090 Free article. Review. Danish.

2

Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.

Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Hasselbalch HC, et al. Among authors: riley ch. Curr Drug Targets. 2011 Mar 1;12(3):392-419. doi: 10.2174/138945011794815275. Curr Drug Targets. 2011. PMID: 21143149 Review.

3

Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.

Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM. Riley CH, et al. Blood. 2011 Aug 25;118(8):2170-3. doi: 10.1182/blood-2011-03-340992. Epub 2011 Jun 27. Blood. 2011. PMID: 21708889 Free article.

4

Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?

Hasselbalch HC, Riley CH. Hasselbalch HC, et al. Among authors: riley ch. Leuk Res. 2006 Oct;30(10):1217-25. doi: 10.1016/j.leukres.2005.12.018. Epub 2006 Feb 17. Leuk Res. 2006. PMID: 16483650 Review.

5

The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders.

Hasselbalch HC, Riley CH. Hasselbalch HC, et al. Among authors: riley ch. Curr Drug Targets. 2007 Feb;8(2):247-56. doi: 10.2174/138945007779940133. Curr Drug Targets. 2007. PMID: 17305502 Review.

6

High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis.

Hasselbalch HC, Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA. Hasselbalch HC, et al. Among authors: riley ch. Leuk Res. 2011 Oct;35(10):1330-4. doi: 10.1016/j.leukres.2011.03.013. Epub 2011 Apr 5. Leuk Res. 2011. PMID: 21470677

7

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: riley ch. Leuk Lymphoma. 2012 Jan;53(1):123-9. doi: 10.3109/10428194.2011.597905. Epub 2011 Aug 1. Leuk Lymphoma. 2012. PMID: 21806350

8

Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.

Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC, Larsen TS. Skov V, et al. Among authors: riley ch. Exp Hematol. 2012 Sep;40(9):771-780.e19. doi: 10.1016/j.exphem.2012.05.011. Epub 2012 Jun 1. Exp Hematol. 2012. PMID: 22659388 Free article.

9

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH. Sørensen AL, et al. Among authors: riley ch. Eur J Haematol. 2019 Oct;103(4):351-361. doi: 10.1111/ejh.13292. Epub 2019 Aug 18. Eur J Haematol. 2019. PMID: 31297883 Clinical Trial.

10

[Flowcytometric diagnostics of hereditary spherocytosis].

Riley CH, Nikolajsen K, Kjaersgaard E, Klausen TW, Mourits-Andersen T, Clausen N, Lausen B, Rosthøj S, Birgens H. Riley CH, et al. Ugeskr Laeger. 2009 Nov 30;171(49):3610-4. Ugeskr Laeger. 2009. PMID: 19954702 Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page